Asia Oncology Drug Market Outlook to 2019 - Market Research Report

·         Future Growth of oncology drug market is expected to be led by countries such as India, China and others

·         The market leader, Roche is expected to maintain focus on Emerging Markets and global brands to compete with other players in the industry.

Ken Research announced its latest publication on “Asia Oncology Drug Market Outlook to 2019 – Rise in Cancer incidences and Ageing Population to Drive the Demand” which provides a comprehensive analysis of the oncology drug market in Asia. The report covers various aspects such as market size of Asia oncology market, segmentation on the basis of type of modalities, treatment, global and local players, and type of cancer. The report also covers India as well as China oncology drug market in different aspects such as market size, segmentation on the basis of type of treatment, cost of treatment and import and export of anti-cancer drugs in the market. The report is useful for oncology drugs manufacturers, hospitals, government association, retail chains and new players venturing in the market.

Asia Cancer Drugs Market

The Asia oncology market has witnessed a growth in recent years on account of rising demand for anti-cancer drugs fueled by increase in healthcare expenditure, rising awareness and affordability.  The surge in growth is majorly originated from growth in Breast and Blood Cancer as a segment of cancer market. The growth is Asia oncology drug market is fueled by growth in markets of India, China and Japan. The growth in these countries has been largely led by the domestic factors such as supportive government policies, increasing demand and entry of new player in oncology drug market. The Asia Oncology drug market is comprised of large companies such as Roche which posses a large product portfolio of oncology drugs. The Asia oncology drug market revenues have grown at a CAGR of 4.3% from 2009-2014.

According to the research report, the Asia oncology drug market will grow at a considerable CAGR and will exceed over USD 20 billion by 2017 due to the increasing number of players, rising incidence of cancer and increasing demand for the oncology drugs

“Boom in ageing population in China and Japan, rising intake of health insurance and an increase in the out of pocket healthcare expenditure will result in increased revenue of oncology drug market in the Asia, volatility in global product prices, enhancing competition and development of generic drugs are few of the major challenges which will affect the growth of this industry in the future”, according to the Research Analyst, Ken Research.

Key Topics Covered in the Report:

Oncology Drugs

-          Market Size by Revenue

-          Market Segmentation by

o   Therapeutic Modalities

o   Generic and Patented Drugs

o   Local Players and Global Players

-          Trends and Development

-          SWOT

-          Export and Import

-          Competition and Market Share

-          Growth Drivers

-          Future Outlook

-          Macro Economic Parameters

-           

Key Products Mentioned in the Report

-          Generic Cancer Drugs

-          Patented Cancer Drugs

-          Chemotherapy

-          Targeted Therapy

-          Hormone Therapy

-          Immuno Therapy

-          Avsatin

-          Herceptin

-          Xalkori

-          Sutent

-          Gleevec

-          Arimidex

-          Revlimid

Companies Covered in the Report

Global Players

-          Roche

-          Pfizer

-          Novartis

-          Celgene

-          GlaxoSmithKline

-          AstraZeneca

-          Eli Lily

Domestic Players-India

-          Cipla Ltd

-          Sun Pharma Pharmaceuticals Ltd

-          Dr Reddy Laboratories Ltd

-          NATCO Pharmaceuticals Ltd

-          Biocon Ltd.

Domestic Players-China

-          Jiang Su Heng Rui Medicine Co. Ltd

-          Qilu Pharmaceuticals Co. Ltd

-          Jiangsu Hansoh Pharmaceutical Co. Ltd

-          Luye Pharma Group Ltd

-          Livzon Pharmaceutical Group

Related Reports:

India Single Specialty Hospitals and Clinics Industry Outlook to 2019 - Day Care Specialty Clinics to Impel Growth

The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth

Source: https://www.kenresearch.com/healthcare/pharmaceutical-industry/asia-cancer-drugs-market-research-report/649-91.html

                            

Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249

Cancer Drugs Market - India, China and Japan Industry Future Outlook and Projection to 2019

Asia Oncology Drug Market Outlook to 2019 – Driven by Rising Demand and Intensifying Joint Ventures between Companies” provides a comprehensive analysis of the oncology drug market in Asia. The report covers various aspects such as market size of oncology drugs, segmentation on the basis of therapeutic class, types of cancer, and volume of exports and imports for oncology drugs. The report is useful for pharmaceuticals companies, retail chains, consultants, healthcare professionals and new players venturing in the market. The market is dominated by few global players including Roche, Novartis, Pfizer and others.

Asia Cancer Drugs Market

Asia Pacific Region

The Oncology drug market in the Asia, which is hugely driven by rising demand and investment level of government, registered revenues of USD ~ million in 2013. With the advent of new oncology drug manufacturers in the industry, the revenues increased by 7.6% compared to 2013 where the total revenues was USD ~ million. Each segment in the anti-cancer drug market is subject to a gamut of different factors such as prevalence rate of specific type of cancer, price cuts and number of players in the market plays an important role in determining their respective revenues.

The oncology drug market of Asia has grown at a CAGR of 4.3% from USD ~ million in’2009 to INR ~ million in 2014. In more developed markets of the Asia-Pacific region, including countries such as Japan and China, the offerings from the market players are expected to be diverse, focused mainly on customized demands. Additionally, the market is predicted to witness expansion in terms of the newer forms of drugs because of rising cancer incidence and growing awareness. The Asia-Pacific oncology drug market is expected to grow at a CAGR of 9.0% from 2015-2019 on account of increasing affluence of consumers towards healthy lifestyles and treatment of cancer in the recent years.

The Asia oncology drug market is dominated by global pharmaceuticals companies that specialize in marketing patented drugs. The market revenues of Roche from sale of anti-cancer drugs have increased noticeably from USD ~ million in 2012 to USD ~ million in 2014, making it the largest player in oncology drug space. Pfizer was the second largest player in 2014. An inclination in the death rates of cancer patients due lack of proper treatment provides a huge opportunity to pharmaceutical companies to deliver effective drugs in the market and thus contributing to higher revenue of anti-cancer drug market.

India

The Oncology drug market in India, which is driven by the development of new alternative therapies, evolving move from chemotherapy to specific cancer targeted therapy, hormone therapy has registered revenues of INR ~ million in 2013. With an entry of new oncology drug manufacturers in the industry, the revenues increased by 65.5% compared to 2013 where the total revenues was INR ~ million. A major factor that has contributed to such a stupendous growth of this market is advances in technologies. Owing to the advancement in technology, the cancer is diagnosed much frequently and thus better treatment can be provided to the patients. The oncology drug market of India has grown at a CAGR of 22.0% from over INR 12 billion in 2009 to INR ~ million in 2014. The main competitors’ in India oncology space includes Cipla Ltd, Sun Pharma Ltd, Dr Reddy Laboratories amongst others. The India oncology drug market is expected to grow at a CAGR of 17.6% from 2015-2019 due to greater influx of patients in cancer care centers due to rising awareness among the people about the right place for best treatment will continue to escalate the growth of oncology treatment in India.

China

Additionally, China has witnessed continuous and substantial rise in the incidence as well as death caused by cancer. This rapid rise has be attributed to factors such as changing lifestyles and dietary patterns, increasing consumption of tobacco, heavy smoking and several other proximate causes. The revenue of oncology market in China increased by 15.0% compared to 2013. The market has grown at a CAGR of 17.3% from USD ~ million in 2009 to USD ~ million in 2014. The market for oncology drugs in China is dominated by local players such as Jiang Su Heng Rui Medicine Co. Ltd, Qilu Pharmaceuticals Co. Ltd and others. The China oncology drug has been anticipated to incline to about USD 30 billion in 2019 from USD ~ billion in 2014. In addition, the share of generic drugs in China Oncology market is expected to rise by a small percentage to around 72% in the year 2019.

The market for oncology drugs in Asia is changing at a rapid rate. Furthermore, new upcoming drugs, investment by government on Healthcare as well as competitive pressures have been significantly changing the market. Revenues from the anti-cancer drug market in the Asia are expected to expand to USD ~ million in 2019 growing with a CAGR of ~% from 2014-2019.

Key Topics Covered in the Report:

• The market size of the oncology drug market in Asia
• The market size of the generic and patented drugs in Asia oncology drug market.
• The market size of the local and global players market Asia oncology drug market.
• The market size of the India oncology and China oncology drug market.
• Market segmentation of the oncology market on the basis of type of cancer, by generic and patented drugs.
• SWOT and Porter Five force Analysis of India and China Oncology Drug market.
• Trends and Development in the Asia oncology drug market.
• Government Regulations in the India and China oncology drug market.
• Competitive landscape detailed company profiles and market share of the major manufacturers of oncology drugs in Asia as well as India, China and others
• Macro Economic factors affecting India and China Oncology drug market.
• Future outlook and projections of Asia Oncology drug market on the basis of – geography.

Source: https://www.kenresearch.com/healthcare/pharmaceutical-industry/asia-cancer-drugs-market-research-report/649-91.html

Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249